Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Argus Health
Express Scripts
AstraZeneca
Merck
Baxter
Accenture
Chubb
QuintilesIMS

Generated: December 12, 2018

DrugPatentWatch Database Preview

Upsher Smith Labs Company Profile

« Back to Dashboard

What is the competitive landscape for UPSHER SMITH LABS, and what generic alternatives to UPSHER SMITH LABS drugs are available?

UPSHER SMITH LABS has seventy-two approved drugs.

There are ten US patents protecting UPSHER SMITH LABS drugs.

There are twenty-two patent family members on UPSHER SMITH LABS drugs in ten countries and forty-one supplementary protection certificates in nine countries.

Summary for Upsher Smith Labs
International Patents:22
US Patents:10
Tradenames:53
Ingredients:48
NDAs:72

Drugs and US Patents for Upsher Smith Labs

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Upsher Smith Labs MIRTAZAPINE mirtazapine TABLET;ORAL 076189-001 Jun 19, 2003 DISCN No No ➤ Sign Up ➤ Sign Up
Upsher Smith Labs VOGELXO testosterone GEL, METERED;TRANSDERMAL 204399-003 Jun 4, 2014 BX RX No No 9,295,675 ➤ Sign Up Y ➤ Sign Up
Upsher Smith Labs CIMETIDINE cimetidine TABLET;ORAL 074506-002 Jan 24, 1996 DISCN No No ➤ Sign Up ➤ Sign Up
Upsher Smith Labs OXANDROLONE oxandrolone TABLET;ORAL 076761-001 Dec 1, 2006 AB RX No No ➤ Sign Up ➤ Sign Up
Upsher Smith Labs MEMANTINE HYDROCHLORIDE memantine hydrochloride TABLET;ORAL 090043-001 Jul 31, 2015 AB RX No No ➤ Sign Up ➤ Sign Up
Upsher Smith Labs MORPHINE SULFATE morphine sulfate CAPSULE, EXTENDED RELEASE;ORAL 202104-004 Jun 3, 2013 AB RX No No ➤ Sign Up ➤ Sign Up
Upsher Smith Labs DOXAZOSIN MESYLATE doxazosin mesylate TABLET;ORAL 209013-001 Apr 17, 2018 AB RX No No ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for UPSHER SMITH LABS drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Extended-release Capsules 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg ➤ Subscribe 2015-12-24
➤ Subscribe Nasal Spray 200 IU/spray ➤ Subscribe 2006-03-29

Supplementary Protection Certificates for Upsher Smith Labs Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB95/010 United Kingdom ➤ Sign Up PRODUCT NAME: 2-N-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL)BIPHENYL-4-YL) METHYL) -5-(HYDROXYMETHYL) IMIDAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT; REGISTERED: SE 12209 19940902; UK 0025/0324 19941215; UK 0025/0336 19941215
C0026 France ➤ Sign Up PRODUCT NAME: RALTEGRAVIR OU L(UN DE SES SELS PHARMACEUTIQUEMENT ACCCEPTABLES EN PARTICULIER UN SEL DE POTASSIUM; REGISTRATION NO/DATE IN FRANCE: EU/1/07/436/001 DU 20071220; REGISTRATION NO/DATE AT EEC: EU/1/07/436/001 DU 20071220
C0055 France ➤ Sign Up PRODUCT NAME: SULFATE DE SODIUM ANHYDRE, SULFATE DE MAGNESIUM HEPTAHYDRATE, SULFATE DE POTASSIUM; NAT. REGISTRATION NO/DATE: NL41696 20130426; FIRST REGISTRATION: 434323 20130220
C/GB99/024 United Kingdom ➤ Sign Up PRODUCT NAME: N-(3-(3-CYANOPYRAZOLO(1,5-A)PYRIMIDIN-7-YL)PHENYL)-N-ETHYLACETAMIDE (ZALEPLON); REGISTERED: UK EU/1/99/099/001 19990312; UK EU/1/99/099/002 19990312; UK EU/1/99/099/003 19990312; UK EU/1/99/099/004 19990312; UK EU/1/99/099/005 19990312; UK EU/1/99/099/006 19990312; UK EU/1/99/102/001 19990312; UK EU/1/99/102/002 19990312; UK EU/1/99/102/003 19990312; UK EU/1/99/102/004 19990312; UK EU/1/99/102/005 19990312; UK EU/1/99/102/006 19990312
315 Luxembourg ➤ Sign Up PRODUCT NAME: COMBINAISON COMPRENANT ALISKIREN,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE,ET AMLODIPINE,OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE
C/GB98/031 United Kingdom ➤ Sign Up PRODUCT NAME: 2-BUTYL-4-CHLORO-1-((2'-(1H-TETRAZOL-5-YL) BIPHENYL-4-YL)-METHYL)-5-(HYDROXYMETHYL)IMIDAZOLE (LOSARTAN),OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, IN PARTICULAR A POTASSIUM SALT( LOSARTAN POTASSIUM) AND HYDROCHLOROTHIAZIDE,; REGISTERED: FR 338520.7 19950215; FR 558453.7 19950215; UK 00025/0338 19960412
00625 Netherlands ➤ Sign Up PRODUCT NAME: COMBINATIE BEVATTENDE ALISKIREN, OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN, EN AMLODIPINE, OF EEN FARMACEUATISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/11/686/001-056 20110414
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
UBS
Boehringer Ingelheim
Covington
Argus Health
Daiichi Sankyo
Harvard Business School
Deloitte
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.